Warner-lambert Company

Reata Pharmaceuticals, Inc.

Abbvie Inc.

Basf Aktiengesellsschaft

Bradley W Caprathe

Juan C Jaen

Xin Jiang

Lawrence D Wise

Melean Visnick

Gary Louis Bolton

Chitase Lee

William Howard Roark

Eric Anderson

Christopher F Bender

Martha R Hotema

Sarah J Smith

Sheryl Jeanne Hays

John Lodge Gilmore

David Juergen Wustrow

Stephen J Johnson

Corinne E Augelli-Szafran

Jonathan L Wright

Dennis M Downing

Horace A DeWald

William J Smith, Iii

Zachary S Sheldon

David J Lauffer

Rolf Wagner

Haile Tecle

Stephen Douglas Barrett

Walter H Moos

Allan C Krueger

Patrick Michael O'Brien

Pamela L Donner

Michael R Pavia

David J Grampovnik

Hui-Ju J Chen

Anthony J Thomas

Howard Robin Heyman

Joseph Scott Warmus

Jason P Shanley

Brian Edward Kornberg

Robert V Talanian

Michael J Rozema

Hamish John Allen

Nigel P Walker

Kenneth Dale Brady

Harry LeVine, Iii

Paul Galatsis

Adam A Galan

Kathryn B Sanders

Jan Ruth Penvose-Yi

Brian Kornberg

Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit RORγ and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.

Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses

Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and RORγ. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.

Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma

Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.

Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions of these derivatives or analogs, methods for their manufacture, and methods for their use, including for the prevention and treatment of diseases or disorders associated with overproduction of IL-17. 

C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses

Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR&#x3b3; and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders. 

Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer. 

Imidazolyl tricyclic enones as antioxidant inflammation modulators

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein R, R, R, R, R, R, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Method of imaging amyloid deposits

The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.

Hydroxamate inhibitors of interleukin-1.beta. converting enzyme

This invention concerns certain 2-substituted-3,1-benzoxazin-4-ones and benzthiazinones as complement Clr protease inhibitors and antiinflammatory agents, pharmaceutical compositions containing them, methods of using them, and processes for their preparation.

2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as

Growing community of inventors

Redford, MI, United States of America

Bradley W Caprathe